Zileuton as a chemopreventive agent for chronic myeloid leukemia

齐留通作为慢性粒细胞白血病的化学预防剂

• 批准号: 9277417
• 负责人: Shaoguang Li
• 金额: $ 34.76万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-01 至 2019-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9277417
• 关键词: Adult; Affect; Anti-Inflammatory Agents; Anti-inflammatory; Apoptosis; Arachidonate 5-Lipoxygenase; Asthma; Bcr-Abl tyrosine kinase; Biological Assay; Bone Marrow Transplantation; CD34 gene; Cell Culture Techniques; Cell Survival; Cell physiology; Cells; Chemopreventive Agent; Child; Chronic Myeloid Leukemia; Colon; Data; Development; Disease; Disease remission; Engraftment; Enzymes; Esophagus; FDA approved; Foundations; Gene Targeting; Genes; Genetic; Human; Imatinib; Immunocompromised Host; In Vitro; Individual; Inflammation Mediators; Inflammatory; Knockout Mice; Leukotriene A4; Leukotriene B4; Leukotriene C4; Leukotriene Production; Leukotrienes; Liver; Lung; Malignant Neoplasms; Metabolic; Modification; Molecular; Mus; Myeloid Leukemia; Nature; Non obese; P-Selectin; Pancreas; Pathway interactions; Patients; Pharmaceutical Preparations; Prevention; Prevention strategy; Production; Publishing; Regulation; Regulator Genes; Relapse; Reporting; Residual state; Role; Signal Transduction; Skin; Solid; Solid Neoplasm; Stem cells; Testing; Transcript; Up-Regulation; Work; Zileuton; abl Oncogene; base; bcr-abl Fusion Proteins; beta catenin; carcinogenesis; chimeric gene; clinically significant; diabetic; hypoxia inducible factor 1; in vitro testing; in vivo; kinase inhibitor; knockout gene; leukemia; leukemic stem cell; novel; novel strategies; peripheral blood; prevent; public health relevance

DESCRIPTION (provided by applicant): This application aims to develop a novel strategy for preventing chronic myeloid leukemia (CML) by targeting leukemia stem cells (LSCs) that initiate CML. This idea is based on our recently published finding that the arachidonate 5-lipoxygenase (5-LO) gene (Alox5) is a key survival-regulatory gene in LSCs (Chen et al. Nature Genetics 41:783-792, 2009), suggesting that Alox5 serves as a potential target gene for preventing CML. A known function of 5-LO is to produce inflammatory leukotrienes, and enzymatic activity of 5-LO can be inhibited by an FDA-approved human anti-inflammatory drug Zileuton (Zyflo). Thus, Zileuton could be a promising chemopreventive agent for CML; the underlying mechanisms are totally unknown and could be related to the effects of Zileuton on the known metabolic function or novel functions of Alox5 or both. Our preliminary studies also show that Zileuton suppresses human CML stem cells. Because CML is derived from a stem cell harboring the BCR-ABL oncogene, our findings prompt us to hypothesize that Zileuton acts on an Alox5-related molecular network responsible for survival regulation of LSCs and is a potential chemopreventive agent for CML. Testing this hypothesis is of clinical significance and would benefit: 1) individuals who have detectable BCR-ABL transcripts but have not developed CML; 2) CML patients who are in molecular remission and hope or have to stop a BCR-ABL kinase inhibitor; and 3) CML patients who had bone marrow transplantation but may still have residual leukemia cells. Mechanistically, because the known Alox5 function is to produce leukotrienes, Zileuton may prevent CML by reducing their production, which needs to be tested. Our preliminary data also reveal novel functions of Alox5, suggesting that Zileuton may suppress Alox5 function through regulating pathways unrelated to production of leukotrienes. In this regard, our preliminary study in shows that loss of P-selectin causes upregulation of Hif1a which enhances Alox5 expression in LSCs and that Alox5 signals to beta-catenin. Inhibition of LSCs by Zileuton provides a novel preventive strategy for CML. In-depth study of Zileuton function helps to identify more Alox5-related target genes for preventing CML and provides a rationale for modifying existing drugs with activities on Alox5 and related genes. The specific aims are: 1) To determine whether leukotrienes promote the survival of LSCs, whether Zileuton suppresses LSCs through reducing leukotriene production and what the underlying mechanism is; 2) To determine the intracellular pathways affected by Zileuton in LSCs; and 3) To determine whether Zileuton similarly regulates the Alox5 pathway in human CML stem cells and reduces engraftment of human CML cells in immunocompromised mice. Although we focus on CML, Zileuton is also a potential chemopreventive agent for solid tumors as Alox5 is associated with carcinogenesis in the colon, lung, pancreas, liver, esophagus, skin.

描述（由申请人提供）：本申请旨在开发一种新的策略，通过靶向引发慢性髓性白血病的白血病干细胞（LSCs）来预防慢性髓性白血病（CML）。这一想法是基于我们最近发表的发现，花生四烯酸5-脂氧合酶（5-LO）基因（Alox5）是LSCs中一个关键的存活调控基因（Chen等）。Nature Genetics 41:783-792, 2009)，提示Alox5可能是预防CML的潜在靶基因。已知5-LO的功能是产生炎性白三烯，fda批准的人用抗炎药Zileuton （Zyflo）可以抑制5-LO的酶活性。因此，Zileuton可能是一种很有前途的CML化学预防剂；潜在的机制是完全未知的，可能与Zileuton对Alox5已知代谢功能或新功能的影响有关，或两者兼而有之。我们的初步研究也表明Zileuton抑制人类CML干细胞。由于CML来源于一种含有BCR-ABL癌基因的干细胞，我们的研究结果提示我们假设Zileuton作用于一个与alox5相关的分子网络，负责LSCs的存活调节，是一种潜在的CML化学预防剂。验证这一假设具有临床意义，并将受益：1)可检测到BCR-ABL转录本但未发展为CML的个体；2)分子缓解，希望或必须停用BCR-ABL激酶抑制剂的CML患者；3)骨髓移植后可能仍有残留白血病细胞的CML患者。从机制上讲，由于已知的Alox5功能是产生白三烯，Zileuton可能通过减少白三烯的产生来预防CML，这需要进行测试。我们的初步数据还揭示了Alox5的新功能，表明Zileuton可能通过调节与白三烯产生无关的途径来抑制Alox5的功能。在这方面，我们的初步研究表明，p -选择素的缺失导致Hif1a的上调，从而增强了Alox5在LSCs中的表达，并且Alox5向β -catenin发出信号。Zileuton抑制LSCs提供了一种新的CML预防策略。对Zileuton功能的深入研究有助于发现更多与Alox5相关的CML预防靶基因，并为修饰现有的Alox5及相关基因活性药物提供理论依据。具体目的是：1)确定白三烯是否促进LSCs的存活，Zileuton是否通过减少白三烯的产生抑制LSCs，其潜在机制是什么；2)确定Zileuton对LSCs细胞内通路的影响；3)确定Zileuton是否类似地调控人CML干细胞中的Alox5通路，减少免疫功能低下小鼠的人CML细胞植入。虽然我们专注于CML，但Zileuton也是一种潜在的实体瘤化学预防剂，因为Alox5与结肠、肺、胰腺、肝脏、食管、皮肤的癌变有关。